Scientific Reports (Dec 2023)
A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib
- Masaki Okamoto,
- Kiminori Fujimoto,
- Takeshi Johkoh,
- Atsushi Kawaguchi,
- Hiroshi Mukae,
- Noriho Sakamoto,
- Takashi Ogura,
- Satoshi Ikeda,
- Yasuhiro Kondoh,
- Yasuhiko Yamano,
- Kosaku Komiya,
- Kenji Umeki,
- Hirotaka Nishikiori,
- Yoshinori Tanino,
- Toru Tsuda,
- Naoki Arai,
- Masamichi Komatsu,
- Susumu Sakamoto,
- Kazuhiro Yatera,
- Yoshikazu Inoue,
- Yasunari Miyazaki,
- Seishu Hashimoto,
- Yasuo Shimizu,
- Hironao Hozumi,
- Hiroshi Ohnishi,
- Tomohiro Handa,
- Noboru Hattori,
- Tomoo Kishaba,
- Motoyasu Kato,
- Minoru Inomata,
- Hiroshi Ishii,
- Naoki Hamada,
- Satoshi Konno,
- Yoshiaki Zaizen,
- Arata Azuma,
- Takafumi Suda,
- Kenji Izuhara,
- Tomoaki Hoshino
Affiliations
- Masaki Okamoto
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine
- Kiminori Fujimoto
- Department of Radiology, Kurume University School of Medicine
- Takeshi Johkoh
- Department of Radiology, Kansai Rosai Hospital
- Atsushi Kawaguchi
- Education and Research Center for Community Medicine, Faculty of Medicine, Saga Medical School
- Hiroshi Mukae
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences
- Noriho Sakamoto
- Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences
- Takashi Ogura
- Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center
- Satoshi Ikeda
- Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center
- Yasuhiro Kondoh
- Department of Respiratory Medicine and Allergy, Tosei General Hospital
- Yasuhiko Yamano
- Department of Respiratory Medicine and Allergy, Tosei General Hospital
- Kosaku Komiya
- Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University
- Kenji Umeki
- Department of Respiratory Medicine, Tenshindo Hetsugi Hospital
- Hirotaka Nishikiori
- Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine
- Yoshinori Tanino
- Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University
- Toru Tsuda
- Kirigaoka Tsuda Hospital
- Naoki Arai
- Department of Respiratory Medicine, National Hospital Organization Ibarakihigashi National Hospital
- Masamichi Komatsu
- First Department of Internal Medicine, Shinshu University School of Medicine
- Susumu Sakamoto
- Department of Respiratory Medicine, Toho University Omori Medical Center
- Kazuhiro Yatera
- Department of Respiratory Medicine, University of Occupational and Environmental Health
- Yoshikazu Inoue
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center
- Yasunari Miyazaki
- Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
- Seishu Hashimoto
- Department of Respiratory Medicine, Tenri Hospital
- Yasuo Shimizu
- Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine
- Hironao Hozumi
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Hiroshi Ohnishi
- Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University
- Tomohiro Handa
- Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University
- Noboru Hattori
- Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University
- Tomoo Kishaba
- Department of Respiratory Medicine, Okinawa Chubu Hospital
- Motoyasu Kato
- Department of Respiratory Medicine, Juntendo University Graduate School of Medicine
- Minoru Inomata
- Department of Respiratory Medicine, Japanese Red Cross Medical Center
- Hiroshi Ishii
- Department of Respiratory Medicine, Fukuoka University Chikushi Hospital
- Naoki Hamada
- Department of Respiratory Medicine, Fukuoka University Hospital
- Satoshi Konno
- Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University
- Yoshiaki Zaizen
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine
- Arata Azuma
- Respirology and Clinical Research Center, Mihara General Hospital and Nippon Medical School
- Takafumi Suda
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine
- Kenji Izuhara
- Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School
- Tomoaki Hoshino
- Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine
- DOI
- https://doi.org/10.1038/s41598-023-49180-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Abstract This study investigated the utility of periostin, a matricellular protein, as a prognostic biomarker in patients with idiopathic pulmonary fibrosis (IPF) who received nintedanib. Monomeric and total periostin levels were measured by enzyme-linked immunosorbent assay in 87 eligible patients who participated in a multicenter prospective study. Forty-three antifibrotic drug-naive patients with IPF described in previous studies were set as historical controls. Monomeric and total periostin levels were not significantly associated with the change in forced vital capacity (FVC) or diffusing capacity of the lungs for carbon monoxide (DLCO) during any follow-up period. Higher monomeric and total periostin levels were independent risk factors for overall survival in the Cox proportional hazard model. In the analysis of nintedanib effectiveness, higher binarized monomeric periostin levels were associated with more favorable suppressive effects on decreased vital capacity (VC) and DLCO in the treatment group compared with historical controls. Higher binarized levels of total periostin were associated with more favorable suppressive effects on decreased DLCO but not VC. In conclusion, higher periostin levels were independently associated with survival and better therapeutic effectiveness in patients with IPF treated with nintedanib. Periostin assessments may contribute to determining therapeutic strategies for patients with IPF.
